United States: To Be Prepared Is Half The Victory

Last Updated: April 28 2016
Article by John M. Clerici

In the second in our series of alerts relating to drug pricing, we identify several considerations and potential actions that a pharmaceutical or biotechnology company can take to address the current headwinds impacting medical innovation at both the federal and state levels. The ultimate outcome of the 2016 elections―presidential, congressional and state―will have a tremendous impact upon any analysis of drug pricing concerns. However, several assumptions can be made, no matter the outcome, that a medical innovator can plan for now, even in advance of the election.

To begin, it is important to focus on the central drivers for the current discussions around drug pricing. In the simplest terms, the debate comes down to two primary concerns about current and projected drug prices: (1) their impact on the cost of health care, with a particular focus on Medicare and Medicaid; and (2) their impact on patients' access to drugs, and any limitations to that access created by pricing.

With respect to the first driver, policymakers at the federal and state level are acutely focused on "big ticket" products that have the potential to negatively affect the solvency of Medicaid and Medicare. The enormous benefit of breakthrough therapeutics that cure, not just treat, Hepatitis C have highlighted that the long-term positive pharmcoeconomic1 value of eliminating the need for liver transplants, and reducing deaths, does not always negate the short-term costs of expensive highly innovative products.

With respect to the second driver, access by patients, the ever-increasing role of patient advocates and patient-centered health care has created powerful grassroots pressure against prohibitively high drug costs, which may deny the most vulnerable populations fair access to life-saving medical innovations. Somewhat ironically, the same groups and forces are the ones pressuring policymakers―including the Food and Drug Administration (FDA)―to remove unnecessary barriers to innovation.

Importantly, neither of these key drivers will be affected by the outcome of the elections.

With this background in mind, we suggest medical innovators that bring to market life-saving therapeutics, vaccines, devices and diagnostics consider the following actions to ensure the current drug pricing debate, and potential ensuing policy changes, do not stifle innovation:

  1. Do your homework upfront before investment. Even with the issue of drug pricing front and center, innovators are not considering the impact of pricing early enough in the investment cycle. Historically, investors often took the view that, when it comes to medicine, if the product works and is approved by the FDA, the product will be "correctly" priced and reimbursed, yielding a reasonable return for investors.

    However, investors now include health outcome, performance, regulatory strategy and pricing as critical decision points when making an investment decision. They therefore need to understand who will pay for the product and how much they'll pay, regardless of whether the technology is a therapeutic, diagnostic or device. Early engagement with an expert in reimbursement and commercial pricing would serve all investors well, including those looking to invest in medicine early in development, to determine whether return on investment is realistic.
  2. Closely monitor and take a role in policy changes. As discussed in our last alert, the Obama administration and Congress, as well as governors and state legislatures, are under tremendous fiscal pressure to address drug pricing, due both to the first driver of cost and political pressure, and to the second driver of patient advocates/access. Extraordinary actions such as invoking federal "march-in" rights have been proposed. As we have noted, for the most part, these proposals have been rebuffed.

    However, without the voice of innovators being heard early and often, the industry as a whole is at grave risk. Significantly, these issues, such as the role of the Bayh-Dole Act, are heavily nuanced and rather complicated. Thus, it is essential to work with an expert in the relevant field, in order to ensure that the political and public relations positions taken by innovators are well grounded.
  3. Consider all implications before going to market. If an innovator has not considered all aspects of pricing early, including reimbursement and the impact upon federal programs, it is essential that all such considerations be analyzed concurrent with completing development of any medical product. Obviously, the economic analysis and business case issues familiar to any commercial entity prior to launch of a product are well known and often considered. However, the better-prepared innovators must take extra steps. These includes early engagement with patient advocates and consideration of the increasing role of a patient-centered, outcome-based private and public health care system.

    It is also critical to examine your footing to defend those positions administratively (through the regulatory process), legislatively (through the political process) and legally (through the courts). All three of these pillars must be thoroughly analyzed and considered, of course along with a traditional marketing and public relations strategy. Given that the issue of drug pricing is at the forefront of the minds of federal and state policymakers, ensuring an early and comprehensive analysis of your actions, and of the likely reactions by regulators, lawmakers and the courts, is key to success.

Dentons and Tiber Creek Partners are available to discuss all aspects of developing a proactive, well-founded drug pricing strategy at any point in the process. Our next advisory on this topic will focus on the development of a reimbursement strategy, which of necessity includes pricing.2


1 Pharmacoeconomics has been defined as the description and analysis of the cost of drug therapy to health care systems and society. More specifically, pharmacoeconomic research is the process of identifying, measuring and comparing the costs, risks and benefits of programs, services or therapies and determining which alternative produces the best health outcome for the resource invested.

2 As an update to the first of these alerts, in which we pointed out that the exercise of retained rights was not a closed issue, on March 28, 2016, a group of House and Senate Democrats asked the National Institutes of Health (NIH) to hold a public hearing to explore whether the NIH's criteria for imposing "march-in authority" to stem drug prices would be met in the case of the cancer drug Xtandi. The letter states: "An open and transparent public hearing on Xtandi by the NIH would help to provide insight into NIH's decision-making process on this case. In addition, we think that a public hearing is important to allow the public to engage in a dialogue with the Department of Health and Human Services and NIH in order to better understand its position on the use of march-in to address excessive prices."

Dentons is the world's first polycentric global law firm. A top 20 firm on the Acritas 2015 Global Elite Brand Index, the Firm is committed to challenging the status quo in delivering consistent and uncompromising quality and value in new and inventive ways. Driven to provide clients a competitive edge, and connected to the communities where its clients want to do business, Dentons knows that understanding local cultures is crucial to successfully completing a deal, resolving a dispute or solving a business challenge. Now the world's largest law firm, Dentons' global team builds agile, tailored solutions to meet the local, national and global needs of private and public clients of any size in more than 125 locations serving 50-plus countries. www.dentons.com.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
18 Sep 2018, Other, Dubai, United Arab Emirates

In December 2017, FIDIC published new editions of the Red Book (Construction), the Yellow Book (Design and Build) and the Silver Book (Turn-key), the first re-write since 1999.

26 Sep 2018, Conference, New York, United States

Dentons is delighted to support a global IT services and consulting firm Miratech as an event host partner at their annual conference called M-Force18 New York on September 27th. The event will be held at Dentons New York office in the heart of Midtown Manhattan, opposite Rockefeller Center.

2 Oct 2018, Seminar, Dallas, United States

We are pleased to offer a program of five sessions designed specifically for in-house counsel. Topics will include:

  • In-house corporate ethical issues
  • What recent Supreme Court decisions mean for business
  • Keeping lawyers out of your benefit plans
  • Litigation tactics for in-house counsel
  • Employment issues in the age of #MeToo
In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions